Cancer Forums and News by PhD's

News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News


Cancer Review


Recent Forum Topics

Biomarker for Avastin
By gdpawel at 2011-11-25 10:07
For some time, clinicians have been grumbling about not having a biomarker for Avastinterm or any other anti-angiogenesis compound to better help choose which patients would be most likely to respond, thereby avoiding the need to treat everyone to gain a benefit in a few.

One of the biggest challenges with Vascular Endothelial Growth Factor (VEGFterm) therapy has been the lack of a predictive biomarker.

read more | 3 comments | 19961 reads

Antivascular activity of lapatinib and bevacizumab in primary microcluster cultures of breast cancer and other human neoplasms
By gdpawel at 2008-09-12 04:09

Antivascular activity of lapatinib and bevacizumabtermterm in primary microcluster cultures of breast cancer and other human neoplasms

Sub-category: New Systemic Agents - New drugs and targets (includes anti-angiogenics) - Other

Category: Treatment

Meeting: 2008 Breast Cancer Symposium

Abstract No: 166

Author(s): L. Weisenthal, D. J. Lee, N. Patel



The following tyrosine kinase inhibitors (TKI) have been shown to have antivascular (AV) activity: sunitinibterm (Su), sorafenibterm (So), gefitinib (G), erlotinib (E), and imatinib (I). To date, AV activity has not been reported for lapatinib (LAP).

read more | 1 comment | 4300 reads

By gdpawel at 2008-08-16 21:53

HUNTINGTON BEACH, CA., August 11, 2008 -  The online edition of the Journal of Internal Medicine reports discovery of the first practical laboratory test to guide the use of new-generation drugs that kill cancer cells by cutting-off their blood supply.  The new test, called the Microvessel Vascular (MVV) assay, was developed by Larry Weisenthal, MD, PhD., a medical oncologist who operates a cancer testing laboratory in Huntington Beach, California.

The test works by measuring drug effects upon endothelial cells which make up blood vessels.  Its use could prolong lives, save money, and spare patients exposure to harmful side-effects of ineffective chemotherapyterm treatments.  The MVV test also could streamline development of new anti-cancer cancer drugs and identify effective and sometimes unexpected new drug combinations, such as one reported in the article.  Used today principally by cancer physicians, to choose effective therapies on a patient-by-patient basis, the MVV assay also has potential for use as an early-warning screen for a variety of illnesses ranging from heart disease, cancer, diabetes, autoimmune disorders, and many others.  Patents have been filed.

read more | 3424 reads

Catch of the day: zebrafish as a human cancer model
By Dross at 2008-07-31 22:50

Zebrafish are making big waves in the field of cancer research. The effect has been widespread and continues to gain speed as more and more cancer researchers ride the wave of zebrafish biology. This has been largely due to the development of transgenic and xenograft models of cancer, which recapitulate many aspects of different human cancers including lymphoblastic T-cell leukemiaterm, pancreatic cancer, melanoma and rhabdomyosarcoma. These models are already being utilized by academia and industry to search for genetic and chemical modifiers of cancer with success. The attention has been further stimulated by the amenability of zebrafish to pharmacological testing and the superior imaging properties of fish tissues that allow visualization of cancer progression and angiogenesis in live animals. This review summarizes the current zebrafish models of cancer and discusses their utility in human cancer research and future directions in the field

read more | 2220 reads

Anti-fungal drug stops blood vessel growth
By Dross at 2007-04-28 01:42

Researchers at Johns Hopkins have discovered to their surprise that a drug commonly used to treat toenail fungus can also block angiogenesis, the growth of new blood vessels commonly seen in cancers. The drug, itraconazole, already is FDA approved for human use, which may fast-track its availability as an antiangiogenesis drug.

In mice induced to have excess blood vessel growth, treatment with itraconazole reduced blood vessel growth by 67 percent compared to placebo. “We were surprised, to say the least, that itraconazole popped up as a potential blocker of angiogenesis,” says Jun O. Liu, Ph.D., professor of pharmacology. “We couldn’t have predicted that an antifungal drug would have such a role.”

read more | 1178 reads

INGN 241 in Combination with Avastin Results in Complete Tumor Regression in Lung Cancer
By HCat at 2007-01-25 10:42

    AUSTIN, Texas--(BUSINESS WIRE)--Jan. 24, 2007--Introgen Therapeutics, Inc. (NASDAQ:INGN) announced today the publication of data in Molecular Therapy, the journal of the American Society of Gene Therapy, highlighting the results of a preclinical study with INGN 241 in combination with Avastinterm(R) (Bevacizumabtermterm). Synergistic activity resulting in a curative therapeutic effect was seen in the treatment of lung cancer following the combination of the two agents. In contrast, treatment with Avastin alone demonstrated only minor tumor regression and no animals were cured of their cancer. The study was conducted at The University of Texas M.D. Anderson Cancer Center by Introgen's collaborator Dr. Rajagopal Ramesh, associate professor, Department of Thoracic and Cardiovascular Surgery.

read more | 4739 reads

Syndicate content

sponsored links



Subscribe to our newsletter to receive info on our site or upcoming clinical trials

Confirm your email address

HTML format

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate

Syndicate content

All times are GMT -5. The time now is 05:23 PM.